|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
IRCT |
|
Last refreshed on:
|
27 April 2013 |
|
Main ID: |
IRCT138903192085N3 |
|
Date of registration:
|
2010-06-09 |
|
Primary sponsor: |
|
|
Public title:
|
Ginkgo biloba effects in the treatment of patients with chronic schizophrenia treated with Risperidone in Joneghan Sinai Hospital
|
|
Scientific title:
|
Ginkgo biloba effects in the treatment of patients with chronic schizophrenia treated with Risperidone in Joneghan Sinai Hospital -
|
|
Date of first enrolment:
|
2009-12-22 |
|
Target sample size:
|
60 in two case and control groups |
|
Recruitment status: |
Complete |
|
URL:
|
http://www.irct.ir/searchresult.php?id=2085&number=3 |
|
Study type:
|
interventional |
|
Study design:
|
Randomization: randomized. Blinding: Double blind. Placebo: used. Assignment: Parallel. Purpose: Treatment. Other design features: .
|
|
|
Countries of recruitment
|
|
Iran, Islamic Republic Of
| | | | | | | |
|
Contacts
|
|
Name:
|
|
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
|
|
|
Name:
|
Neda Parvin
|
|
Address:
|
Rahmatie, Shahrekord, Iran
8814613785
Shahrekord
Iran, Islamic Republic Of |
|
Telephone:
|
00983813335648 |
|
Email:
|
np285@yahoo.com |
|
Affiliation:
|
Shahrekord University of Medical Sciences, Rahmatie, Shahrekord |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Inclusion criteria: Schizophrenia diagnosis
Exclusion criteria: Use of other herbal medicines, aspirin or anticoagulant drugs, clotting problems before and during treatment with Ginkgo
Exclusion criteria:
Age minimum:
18
Age maximum:
80
Gender:
Both male and female
|
|
Health Condition(s) or Problem(s) studied
|
Schizophrenia
Schizophrenia
|
|
Intervention(s)
|
|
Intervention 1: Routine treatment plus 4mg risperidone three times daily and Ginkgo biloba tablet in three doses of 80 mg daily (240 mg) for 12 weeks.. Intervention 2: Routine treatment and 4mg risperidone three times daily and placebo for 12 weeks.
|
|
Primary Outcome(s)
|
|
Improve positive and negative signs . Timepoint: at the begining, 2, 4, 6, 8, 12 weeks after treatment and one month after end of treatment. Method of measurement: complete Anderson positive and negative questionnaire
|
|
Source(s) of Monetary Support
|
|
Shahrekord University of Medical Sciences
|
|